On October 20, 2020, Anchiano Therapeutics Ltd. appointed Andrew Fine, age 50, to serve as the Chief Financial Officer of the Company, effective immediately. Mr. Fine previously served as the Company's Interim Chief Financial Officer pursuant to an arrangement with his employer, Line Consulting A.S Ltd. Mr. Fine has served as the Company's Interim Chief Financial Officer since July 2020. Mr. Fine has more than 20 years of experience in executive financial and operational roles and is currently Co-Managing Director at Line Consulting Ltd. Mr. Fine previously held roles as Chief Financial Officer at Seeking Alpha, ScaleMP and Freightos, leading finance and operations for the companies' global activities.